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Simple Summary: Knowledge extraction from cancer genomic studies is continuously challenged
by the fast-growing technological advances generating high-dimensional data. Network science is a
promising discipline to cope with the resulting complex and heterogeneous datasets, enabling the
disclosure of the molecular networks involved in cancer development and progression. We present
a narrative review of the network-based strategies that have been applied to glioblastoma (GBM),
a complex and heterogeneous disease, along with a discussion on the relevant findings and open
challenges and future research opportunities.
Abstract: Network science has long been recognized as a well-established discipline across many
biological domains. In the particular case of cancer genomics, network discovery is challenged by
the multitude of available high-dimensional heterogeneous views of data. Glioblastoma (GBM) is
an example of such a complex and heterogeneous disease that can be tackled by network science.
Identifying the architecture of molecular GBM networks is essential to understanding the information
flow and better informing drug development and pre-clinical studies. Here, we review network-based
strategies that have been used in the study of GBM, along with the available software implementations
for reproducibility and further testing on newly coming datasets. Promising results have been
obtained from both bulk and single-cell GBM data, placing network discovery at the forefront of
developing a molecularly-informed-based personalized medicine.
Keywords: network analysis; differential network expression; model regularization; causal discovery;
multi-omics; biomarker selection; precision medicine; personalized therapy
1. Molecular Networks in Precision Oncology
The discovery and molecular characterization of cancer subtypes harboring distinct
molecular features and heterogeneous treatment responses comprise a crucial step in can-
cer treatment and management, as different cancer subtypes may respond differently to
available treatment options [1]. Similarly, the stratification of tumor cells into distinct
subpopulations provides valuable insights into the molecular drivers of intratumor hetero-
geneity, a major issue responsible for treatment failure and drug resistance and compromis-
ing personalized-medicine approaches [2,3]. Remarkable advances in the field have been
reached thanks to the growing availability of molecular data delivered by next-generation
sequencing (NGS) technologies, which combine, for a given patient, high-dimensional data
from multiple omics platforms. In most statistical and machine learning-based tools that
have been proposed to this end, molecular phenotypes are treated as single, non-interacting
entities in the global molecular network context.
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Network science has been widely used in the study of the topology and community
structures of real-world networks [4]. In the biomedical domain, network science has
emerged as a powerful tool to study biological systems governed by complex networks.
Biological networks remain as one of the most studied classes of networks. Biological
systems can be represented by networks, with nodes represented by distinct elements (e.g.,
genes, proteins, metabolites) and edges the interaction between the elements. Examples of
biological networks are gene regulatory networks, gene coexpression networks, protein-
protein interaction networks, signaling, and metabolic networks. Network analysis extends
the identification of individual key elements in the biological network to disclosure sub-
networks within the global complex network and how they relate to function and disease.
Understanding how these complex networks function has important clinical implications,
in particular in the definition of molecularly-informed diagnostic, prognostic, and disease
prevention strategies.
The rise of network science in cancer genomics has opened new avenues for the
identification of the networks involved in cancer processes, by the identification of the
molecular network structures involved in cancer development and progression. Such
network-based information can be further used to drive predictive models for future
outcomes to more biologically meaningful solutions, towards a more personalized clinical
and therapy decision, perfectly in line with the precision medicine framework.
In this narrative review, we cover many aspects of network science and examples
of applications in the study of glioblastoma (GBM), a type of cancer characterized by a
marked spatial and temporal heterogeneity at both the cellular and molecular levels [5].
Among the network-based strategies proposed to model GBM molecular data, particular
attention is given to critical steps in GBM molecular characterization and stratification,
namely differential network analysis, gene coexpression module detection, trans-omics
network discovery, cancer subtype identification, biomarker discovery, and causal inference
(Figure 1). A list of the computational tools and biological databases generated from the
studies covered is also provided (Table 1), as well as a summary of the key findings and
major signaling pathways involved in GBM (Figure 2). For the literature search, we used an
automated search via the digital libraries of two major databases (Google Scholar and Web
of Science), using several search string combinations of relevant keywords. A subsequent


















Figure 1. Overview of the current strategies in precision medicine for network learning in glioblastoma.
Cancers 2021, 13, 1045 3 of 22
Figure 2. Simplified summary of major signaling pathways in glioblastoma and examples of genes
previously identified by various network analyses.
2. Network Discovery in Glioblastoma
GBM is the most frequent primary malignant brain tumor in adults [1] and one of the
most aggressive cancers [6,7], with a median survival of approximately 15 months after
diagnosis [8,9]. GBM exhibits extensive tumor heterogeneity, both within and between
tumors [6], which poses major challenges to diagnosis and treatment [10].
Verhaak et al. (2010) [1] performed multi-omics profiling of GBM tumors to disclose
the molecular nature of GBM heterogeneity. The analysis revealed four major molecular
subtypes based on transcriptomics, named classical, neural, proneural, and mesenchymal,
which have recently been revised to three, classical, proneural, and mesenchymal [11].
The formerly identified neural subtype was not detected in the latter study, but it has rather
been associated with tumor margin and normal neural lineage [12], probably explained
by sample contamination with normal tissue in the first analysis [11]. Each identified
molecular subtype is characterized by a panel of genetic alterations; in a simplistic manner,
classical, mesenchymal, and proneural GBM subtypes are characterized by modifications
in EGFR, NF1, and PDGFRA/IDH1, respectively [1]. This molecular classification of GBM
impacts clinical outcome, as patients with primary and/or recurrent mesenchymal GBM
commonly present a particularly dismal survival compared to non-mesenchymal cases [11].
Proneural GBM patients have a trend of increased survival, but do not benefit from inten-
sive therapies, contrary to classical and mesenchymal GBMs [1]. Besides the associations
between the molecular subtype and therapy response, MGMT methylation—a known
predictive biomarker of response to standardized temozolomide treatment [13]—was not
associated with the transcriptional subtypes [1]. Upon GBM recurrence, the majority of
the cases maintained the same molecular subtype signature as the primary tumor, partic-
ularly in the case of mesenchymal GBM. This notwithstanding, a significant proportion
of tumors switched molecular subtype after treatment, with an increment of proneural
and mesenchymal GBMs [11]. Despite all the efforts to find similarities among the vast
heterogeneity of GBMs, single-cell RNA sequencing analyses later performed by Patel et al.
(2014) [10] revealed an even more complex level of heterogeneity in GBM, in which par-
ticular individual tumors contained distinct cells with transcriptional profiles resembling
the various molecular subtypes firstly identified by Verhaak et al. (2010) [1]. Thus, while a
predominant molecular subtype can be identified with bulk data generated at the popula-
tion level, more refined single-cell sequencing analyses identify multiple clones associated
with different GBM molecular subtypes in a single tumor. In addition, this study also
found the existence of “hybrid” cells, i.e., individual cells with the representation of more
than one subtype [11]. Interestingly and even though patients whose GBM is classified
as proneural present a trend of increased survival [1], when this subtype is subdivided
into pure proneural, low-heterogeneity proneural, and high-heterogeneity proneural, the
increased heterogeneity of this class lowers the survival of patients, highlighting the clinical
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relevance of intratumoral heterogeneity [10]. Overall, these findings clearly highlight the
remarkable level of complexity regarding the heterogeneity of GBM, potentially applicable
to other cancer types. Network discovery is particularly relevant in the case of highly
heterogeneous cancers, for which network-based machine learning from large-scale and
multi-level NGS data at both bulk and single-cell levels is expected to provide a deeper
insight into GBM’s molecular mechanisms of disease development and progression.
2.1. Differential Network Analysis
One of the most common tasks in genomics is the identification of differentially
expressed genes (DEG) across different disease conditions or cell types. This practice,
although of recognized value for biomarker discovery and the development of targeted
therapies, misses the overall network information genes carry while co-expressed in com-
mon regulatory pathways. To fill this gap, the differential network analysis in genomics
(DINGO) model [14] (Table 1) was proposed for estimating group-specific networks and
inferring differential networks. The method jointly estimates the group-specific conditional
dependencies by decomposing them into global and group-specific components.
In the context of GBM, DINGO was applied to TCGA data from multiple omics
platforms (mRNA expression, DNA copy number, methylation, and microRNA expression)
with the goal of building differential networks for long- and short-term survivors (LTSs
and STSs, respectively). The application focused on selected key signaling pathways
(RTK/PI3K, p53, and Rb), involved in cell migration, survival, and apoptosis and closely
associated with GBM biology.
The differential networks between GBM LTSs and STSs estimated from the different
omics platforms revealed many hub genes with several important roles in GBM progres-
sion, e.g., via a connection with the c-Myc gene, associated with GBM proliferation and
decreased survival. Amongst the differentially expressed hub genes, PDPK1, detected
in the DNA copy number network, promotes EGFR activation [15], a known driver of
GBM cell proliferation, invasiveness, motility, angiogenesis, and apoptosis evasion [16],
contributing to GBM’s aggressiveness. PI3K genes identified from mRNA expression,
DNA copy number, and methylation are frequently altered in GBM (88% of GBMs present
alterations to the RTK/RAS/PI3K axis) [17], supporting pro-tumor effects such as pro-
liferation, growth, differentiation, survival, and angiogenesis [18,19]. From the DNA
methylation data, the hub FOXO1A gene was associated with MLLT7 (FOXO) and with
PIK3CA (PI3K) [14]. The regulatory networks including mTORC2, FOXO, and c-Myc are
highly intercorrelated with a shorter survival of GBM patients [20]. A previous study
had already demonstrated the following connections: by acetylation, mTORC2 is able
to impede FoxO activity that could surpass PI3K/AKT inhibition, upregulating c-Myc.
In the clinical setting, acetylated FoxO and c-Myc were highly correlated in GBM samples,
and patients expressing high levels of c-Myc showed a significantly shorter overall sur-
vival [20]. Reports on in vivo data additionally suggest c-Myc as a potential therapeutic
target in GBM [21] and as an important player in PARP inhibition resistance [22]. The hubs
from microRNA expression revealing a higher degree of connectivity were hsa-miR-103
and hsa-miR-107 [14], which directly interact with the CDK5R1 3’UTR [23], an activator of
CDK5 [24], which is overexpressed and oncogenic in GBM [25–30].
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Table 1. Glioblastoma databases and software tools used in the studies covered by the survey.
Resource Website Ref.
Genome projects
The Cancer Genome Atlas (TCGA) https://www.cancer.gov/tcga [17]
Rembrandt https://gdoc.georgetown.edu/gdoc/ [31]
Gene Expression Omnibus (GEO) https://www.ncbi.nlm.nih.gov/geo/ [32]
NCBI Sequence Read Archive (SRA) https://www.ncbi.nlm.nih.gov/sra [33]
Glioblastoma Bio Discovery Portal https://gbm-biodp.nci.nih.gov/ [34]
Cancer Cell Line Encyclopedia (CCLE) https://portals.broadinstitute.org/ccle [35]
















2.2. Gene Coexpression Module Detection
Uncovering gene coexpression modules, or groups of highly coexpressed genes,
has been pointed out as a promising therapy research direction for the identification and
validation of novel molecular targets, through understanding of how gene modules interact
with cancer lesions.
Horvath et al. (2006) [50] performed gene expression profiling on RNA from 120 GBM
patient samples from two independent datasets. The identification of gene modules was
performed via weighted gene coexpression network analysis (WGCNA) [37,51] (Table 1),
by constructing a weighted gene coexpression network based on the pairwise Pearson
correlations between the gene expression profiles, followed by an unsupervised hierar-
chical clustering to detect groups of highly coexpressed genes. For the first GBM dataset,
the authors detected five gene coexpression modules, which were significantly enriched
for genes across the ontological classes mitosis cell cycle, immune response, neurogenesis,
cytoplasm, and metabolism. The same five gene modules were obtained for the second
dataset, after weighted gene coexpression network construction based on the genes found
for the first dataset, indicating that gene coexpression modules are highly preserved in
both GBM datasets.
Among the various findings of the study, the analysis identified a mitosis/cell cy-
cle module in GBM that is downstream of the mutant epidermal growth factor receptor,
EGFRvIII, as shown by studies done in an isogenic model system. Furthermore, ASPM
(abnormal spindle-like microcephaly associated) was identified as a key gene in the mito-
sis/cell cycle module, being associated with increased cell proliferation, underexpressed
in normal tissue compared to GBM. The results also suggested ASPM’s involvement in
GBM pathogenesis by promoting a stem cell phenotype, therefore supporting ASPM as
a potential GBM molecular target [50]. Shortly after, ASPM was associated with glioma
grade, showing increased expression from non-tumoral samples to grade II, III, and IV
gliomas [52,53]. More recently, ASPM was also associated with the survival of patients
with GBM [50,54] and glioma [55], indicating that the hub genes identified by Horvath et al.
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(2006) [50] might be new prognostic biomarkers. Interestingly, ASPM was previously
identified to be expressed at higher levels in secondary GBMs as compared to lower grade
astrocytomas [56] and was further validated in another study as one of the six genes with
the highest relative expression in GBM compared to pilocytic astrocytomas [57]. ASPM also
emerged as a hub gene in additional screening studies in GBM [55,58,59], and its functional
relevance was recently validated in vitro and in vivo [55]. Specifically, ASPM-silenced GBM
cells presented decreased proliferation rates and formed in vivo subcutaneous tumors with
significantly reduced sizes. Mechanistic assays suggested an association between ASPM
and the Wnt/β-catenin pathway, highly relevant in GBM, and that ASPM knockdown
was linked to a G0/G1 arrest of GBM cells [55]. Globally, this is a paradigmatic example
on the use of network analysis that allowed the identification of a novel GBM biomarker,
with critical oncogenic functions and prognostic clinical potential, for which novel smart
therapies can be developed in the future.
Since it was first proposed, WGCNA has been extensively applied in subsequent
studies on the gene coexpression relationships across glioma subtypes to identify key
genes and pathways associated with the occurrence, progression, and survival of GBM
(e.g., [60–68]).
Disease module extraction (DiME) is another algorithm to identify disease modules
from biological networks [38] (Table 1), built up the community extraction (CE) module
criterion originally proposed for social network analysis [69]. In a study of the molecular
mechanisms involved in glioma progression, Liu et al. (2014) [38] developed novel heuris-
tics to optimize CE and incorporated the B-score, a measure of statistical significance, to
evaluate the quality of the modules extracted from low- (grade II) and high-grade (GBM)
glioma co-expression networks.
The datasets used consisted of microarray expression data from 97 grade II patients
and 126 GBM samples, retrieved from the Rembrandt database (Table 1). Further validation
was performed on the TCGA GBM dataset and the grade II glioma expression dataset
(GSE30339) from the Gene Expression Omnibus (GEO) database (Table 1), consisting of
197 and 23 samples, respectively. From grade II gliomas to GBM, a shift in network
topology was observed, with GBM tumors showing altered levels of transcripts involved
in extracellular matrix (ECM) reorganization and angiogenesis, which stand as markers of
a more aggressive phenotype. The analysis also identified several statistically significant
modules that were reproducible across the different datasets, from which the transcription
factors E2F4, AR, and ETS1 are highlighted as potential key regulators in tumor progression.
E2F4 is overexpressed in high-grade gliomas (HGGs) and is associated with poorer survival
outcome [70]. Interestingly, AR was later found overexpressed in GBMs [71–73] and
associated with poor survival of patients with low-grade gliomas (LGGs) [72]. A growing
body of evidence also suggests AR as a modulator of treatment response in GBM, for
example: (i) AR confers radiation resistance [73]; (ii) the nuclear translocation of AR is
affected by cedrol treatment, suppressing GBM progression [74]; (iii) the 5α-reductase
enzyme inhibitor dutasteride in combination with AR antagonists effectively decreased
the proliferation of GBM cells [75]; and (iv) a curcumin analog induced the ubiquitination
of AR and consequent degradation, suppressing the growth of temozolomide-resistant
cells [76]. Similarly, ETS1 had also been studied for its impact in the expression/regulation
of other genes in brain tumors, such as uPA and Flt-1/VEGFR-1 in astrocytic tumors [77,78]
and DPP-III when conjugated with Elk-1 in human GBM [79]. More recently, ETS1 was
also found to transcriptionally activate the C250T mutant form of the TERT promoter [80],
which has been recognized as a critical driver of replicative immortality in GBM [81,82].
To identify gene expression relationships across multiple human tumors, Dunwoodie
et al. (2018) [83] used the Knowledge-Independent Network Construction (KINC) soft-
ware [39] (Table 1) to build two RNAseq-based gene coexpression networks based on
publicly available datasets from TCGA (GBM; LGG; bladder urothelial carcinoma; thyroid
carcinoma; and ovarian serous cystadenocarcinoma) and the NCBI Sequence Read Archive
(SRA) (GBM, normal brain, and Parkinson’s brain) (Table 1). KINC uses Gaussian mixture
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models (GMMs) before applying pairwise correlation analyses to the gene expression ma-
trices. The major feature of KINC is its ability to deconvolute mixed-condition expression
patterns (e.g., mixed tumor expression profiles from GBM and non-GBM samples) without
the need to separate gene expression profiles before analysis.
A 22-gene GBM-specific module was identified in the two gene expression sources.
The module showed increased RNA expression compared to normal brain and LGG
samples and decreased DNA methylation in GBM in relation to LGG. Moreover, seventeen
of the 22 shared genes were found in the Glioblastoma Bio Discovery Portal (GBM-BioDP)
(Table 1) based on results from Verhaak et al. (2010) [1]. The highest expression for these
genes was observed for the mesenchymal subtype, and high expression was associated
with decreased survival in each GBM subtype. Four genes (SIGLEC9, MYO1F, LAPTM5,
ITGB2) from the 22 gene list were upregulated in mesenchymal GBM. Interestingly, recent
data indicated ITGB2 as being highly positively correlated with the tumor-associated
macrophage (TAM) marker CD68 [84], suggesting an increased infiltration of TAMs in
ITGB2-positive gliomas. Furthermore, higher expression of ITGB2 was associated with
shorter overall survival of glioma patients [84]. These data are in agreement with the
study of Wang et al. (2017) [11], in which the authors identified an increment of infiltrating
macrophages in mesenchymal GBMs and shorter survival of this subtype [11].
2.3. Trans-Omics Network Discovery
The rapid advances in sequencing technologies have enabled the acquisition of patient
molecular information by diverse omics assays. With the great amounts of molecular
information generated per patient, it became possible to explore the relationships among
molecular features across different omics layers, e.g., DNA variants and downstream
phenotypes, and potentially identify trans-omics therapeutic targets.
The first method we showcase extends DINGO (Section 2.1) to integrate matrices of
expression data on the same samples from different platforms (iDINGO) [85] for a deeper
biological understanding of the relationships across the omics layers. The method estimates
group-specific dependencies and makes inferences on the integrative differential networks,
considering the biological hierarchy among the platforms.
Jörnsten and co-authors (2011) [86] addressed the challenge of uncovering how DNA
copy number aberrations (CNAs) affect gene expression, via endogenous perturbation
analysis of cancer (EPoC), a method that constructs mRNA-based network models in which
mRNA patient profiles are regarded as responses to perturbations induced by CNAs during
tumor evolution. The goal is to detect disease-driving CNAs, assess their effect on target
mRNA expression, and disclose GBM biomarkers, which are predictors of patient survival.
To identify the transcriptional and CNA–mRNA couplings, EPoC solves the two
complementing linear systems, one representing the transcriptional interaction network
and the other the CNA-driven network, consisting of CNA–mRNA interactions. EPoC
first uses a combination of lasso regression and bootstrapping to estimate the parameters
of the EPoC network model from paired DNA- and RNA-level data. Then, a score based
on sparse singular-value decomposition of the derived CNA–mRNA network model is
computed to disclose prognostic biomarkers able to stratify patients into LTSs and STSs.
The method was applied to TCGA GBM datasets (CNA and mRNA), based on
10,672 genes and 186 patients. Known disease-driving CNAs controlling multiple down-
stream hub genes could be identified, namely oncogenes and tumor suppressors with
a known role in GBM, including EGFR, PDGFRA, CDKN2A, and CDKN2B, but also
other interesting hub genes not previously associated with GBM, e.g., MTAP and SEC61G.
The model also detected robust CNA–mRNA links between the hubs EGFR, PDGFRA,
and CHIC2 and markers of early neural development, such as a GBM stem cell marker,
CD133 (PROM1), and the transcription factors SOX10, SOX11, NR2E1 (TLX), and NKX2.2.
From all these pinpointed genes, the impact of MTAP, SEC61G, CD133, and SOX11 was
previously evaluated in GBM patients. MTAP has been implicated as a prognostic factor,
despite discordant findings: MTAP deletion was associated with decreased progression-
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free survival in GBM patients [87], while another study reported that adult GBM patients
lacking MTAP expression had better survival than those with detectable levels of MTAP
expression [88]; SEC61G’s higher expression was linked to decreased overall survival of
patients from TCGA [89]; SOX11 overexpression was reported to be associated with longer
overall survival [90,91]; finally, the impact of CD133 in patient prognosis is quite contro-
versial, but a recent meta-analysis of published data concluded that higher expression of
CD133 is associated with poorer prognosis [92]. The results obtained by the CNA-driven
GBM network model were further validated in four GBM cell lines (T98G, U-87MG, U-
343MG, and U-373MG), via perturbations on NDN, which encodes the p53-interacting
protein necdin, to suppress GBM cell growth. In the resulting CNA-driven network, NDN
shares a target, fibroblast growth factor 9 (FGF9), with PDGFRA, which is frequently
amplified in GBM.
Multiple microRNAs (miRs) have been described as promoting or suppressing oncoge-
nesis, as modulators of gene expression. Genovese et al. (2012) [93] inferred putative GBM
regulatory networks between miRs and mRNA GBM data using the context-likelihood-
relatedness (CLR) [46] algorithm. The dataset counted for 290 matched miR and mRNA
expression profiles, yielding a total of 26,297 edges between 254 miR and 6152 mRNA.
CLR generates pair-wise associations based on mutual information (MI). The algo-
rithm involves a statistical background correction step, in which the significance of each
miR-mRNA MI value is assessed against the background distribution of MI scores for all
possible miR/gene pairs that include either the miR or its target. After this background
correction, the most probable interactions are those whose MI scores stand signficantly
above the background distribution of MI scores. The analysis suggested a role of mRNA
regulation by miR in the definition of the molecular proneural and mesenchymal subtypes,
revealed by the marked expression differences in the edges obtained for the global network
between these subtypes. miR-34a expression was found to be prognostic in GBM, in both
TCGA and an independent cohort of human gliomas, with miR-34a low-expressing GBM
patients exhibiting an overall improved survival. The same results were obtained for the
proneural subtype. Evidence of miR-34a as a tumor suppressor in proneural GBM was
also obtained by integrative in silico analyses, functional genetic screening, and experi-
mental validation [93]. A direct regulation of PDGFRA by miR-34a, previously found as
functionally related to proneural GBM [94], was also confirmed. Additionally, promoter
enrichment analysis of the edges identified uncovered a novel regulation of TGFβ signaling
via a Smad4 transcriptomic network by miR-34a [93], later shown to be implicated in the
regulation of GBM cells’ migration and invasion [95].
2.4. Network-Based Learning
2.4.1. Cancer Subtype Identification
Cancer genomic profiling has been extensively used to stratify cancer samples into
well-characterized molecular subtypes towards improved diagnosis and prognosis. The in-
creasing availability of information from biological networks from multiple molecular
assays has motivated researchers to incorporate such invaluable information into the
learning procedure.
Xu et al. (2016) [40] addressed the problem of identifying cancer subtypes, by devel-
oping the weighted similarity network fusion (WSNF) method (Table 1). WSNF is based
on a previously proposed method, similarity network fusion (SNF) [96], a multi-omics
data fusion method that stratifies patients into cancer subtypes based on a fusion similarity
matrix obtained from the similarities between patients from different data types and a
subsequent clustering step. WSNF extends SNF to make use of available information on
biological networks, such as gene regulatory networks, by incorporating feature weights
(i.e., feature importance) into the clustering process for cancer subtype identification from
multi-omics data, which are obtained by combining features’ ranking in the network and
their expression variation.
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In an application to the TCGA GBM dataset, WSNF was built on gene expression data
and information from a complex miRNA-TF-mRNA regulatory network, with the nodes
representing the features, i.e., miRNA, transcription factors (TF), and mRNAs, and the
edges of the interactions between them, the latter retrieved from interatomic databases.
In this study, WSNF was able to identify three GBM subtypes with significantly different
survival patterns and enriched pathways.
GBM subtype identification was also approached via CSPRV (cancer subtype pre-
diction using RV2) [41], a method that overcomes previous methods also integrating
multi-source transcriptome expression and biological networks for cancer subtype predic-
tion, by considering the data-view weights in data integration, the importance of features,
and their relationships in data integration. CSPRV is a multi-step procedure that first
extracts multiple expression features of each regulatory element based on the regulatory
associations in the biological networks; then, it reduces the high-dimensional expression
features extracted to a low-dimensional space and constructs an integrative feature matrix
for each sample; it uses a matrix correlation method, RV2 [97], to predict the similarities
between samples in each expression data-view, which are then fused according to the
different integration weights; and finally, it clusters samples into different groups based on
the integrated similarities between samples. CSPRV showed improved performance in the
identification of GBM subtypes with different survival patterns over WSNF.
2.4.2. Model-Based Biomarker Discovery
One of the biggest challenges in the identification of predictive models for cancer
outcomes and key drivers of disease processes is the problem of the high-dimensionality
of molecular data matrices. The incorporation of model regularizers in generalized linear
regression frameworks has shown promise in both predictive model performance and
feature selection across many biomedical contexts (see [98]). These include the least
absolute shrinkage and selection operator (lasso) [99], elastic net [100], fused lasso [101],
along with variants such as adaptive lasso [102] and group lasso [103]. However, these
strategies rely solely on data and the computational aspects of algorithm implementation,
without incorporating any prior information on the biological processes.
The remarkable technological advances in the last few decades and great efforts of
large consortia, e.g., through genome- and proteome-wide projects, have produced a vast
amount of molecular and pathway information now available through biological databases
(Table 1). Regulatory networks can be represented by graphs, where the nodes or vertices
represent the genes or gene products and the edges the relationships among them. To take
advantage of such a massive amount of valuable information, several methods have been
proposed to incorporate information from these graphs, e.g., pathway topology, into model
generation, leading to more interpretable solutions.
Li and Li (2008) [104] introduced a network-constrained penalty function to identify
genes and subnetworks that are related to phenotype responses. The regularizer penalizes
the `1-norm (lasso) of the coefficients while encouraging the smoothness of the coefficients
on the network through a graph Laplacian constraint. The proposed network-constrained
procedure was applied to a GBM microarray gene-expression dataset [104] on 50 patients
and 1533 genes found in the Kyoto Encyclopedia of Genes and Genomes (KEGG) network
of 33 pathways. The method was successful in the identification of subnetworks of the
KEGG pathways that were related to patient survival from GBM, some of them supported
by previous studies. Among the subnetworks identified, the largest included genes involv-
ing the MAPK signaling pathway (e.g., PLCE1, PRKCG, MAP2K7, ZAK, KBKG, TRAF2, and
MAPK11) and its connected pathways, such as the PI3K/Akt signaling pathway (e.g., gene
GYS1) and its target FOXO1A [105,106]. Another subnetwork identified four genes, PTEN,
PRKG2, MAPK8IP2, and ELK1. PTEN is a negative regulator of PI3K signaling [107,108],
frequently dysregulated in GBM; the PRKG2 gene encodes cyclic guanosine monophos-
phate (cGMP)-dependent protein kinase II and is responsible for anti-proliferative signals
in human gliomas [109]; the MAPK8IP2 gene encodes a JNK-interacting protein, influenc-
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ing JNK and p38MAPK signaling [110], which are pivotal in GBM [111,112]; and ELK1
is a downstream target of PKCη-, and its activation results in increased proliferation in
GBM cell lines [113]. The gene pairs subnetworks also revealed genes with a previously
reported role on GBM, namely the CTNNB1 [114,115], CTLA-4 [116], and CLDN gene
families [117,118].
Other strategies for accounting for network-based information during the learning
process encompass the introduction of weights in the coefficients, which can be derived
either from the network topology of external databases (e.g., protein-protein interaction
databases) or of the data network structure itself, e.g., the correlation/covariance ma-
trices, as shown in survival and classification on breast, melanoma, and ovarian cancer
datasets [42,43,119–121], using available implementations in the R packages glmnet [122]
and glmSparseNet [42] (Table 1). Considering the elastic net regularizer, this is equivalent
to adding a weight factor to the penalty term.
Under the regularized-based learning framework, a variant of the above correlation-
based regularizers, the twin networks recovery (twiner) penalty was introduced by
Lopes et al. (2020) [123,124] to explore the differences in the gene correlation networks in
a classification setting. Given two disease types, the goal is to select features that have a
similar correlation pattern across the two conditions, which can be regarded as putative
disease targets for the development of shared therapeutic approaches for the two diseases.
The twiner regularization weights are built based on the similarities given by pairwise
correlations between the variables independently obtained from two given datasets (dis-
ease types/conditions). For a given variable (gene), the lower the distance between the
correlation vectors in the two disease conditions, the lower the penalty induced on that
gene. These ideas have been recently extended to survival modeling via the TCox [125],
intended to select variables with distinct correlation patterns across two group conditions,
e.g., cancer vs. normal tissue, which have a relation to the survival outcome.
The suitability of the above network-based regularizers has been shown to be promis-
ing when tackling GBM heterogeneity via biomarker selection and classification [123] in
a single-cell RNA sequencing (scRNA-seq) GBM dataset [126]. The authors proposed a
classification setting through sparse logistic regression to classify cells into different popu-
lations (neoplastic and normal cells), while selecting gene features discriminating between
classes, but also those shared by different neoplastic clones (tumor core and infiltrating
cells), standing as putative therapeutic markers to target multiple clones.
Among the genes revealed by the analysis, several have a known role in GBM, in par-
ticular: three upregulated genes in GBM infiltrating tumor cells with known functions
involving the invasion of the interstitial matrix, ATP1A2, PRODH, and FGFR3 [126]; the
epidermal growth factor receptor (EGFR), upregulated in neoplastic periphery astrocytes
and significantly mutated in GBM [127,128]; ANXA1, upregulated in infiltrating astrocytes,
promoting GBM tumor growth and progression [129] and correlated with IGFBP2, also
selected and upregulated in GBM; the serine protease HTRA1, downregulated in neo-
plastic periphery astrocytes, a binding partner of the macrophage migration inhibitory
factor (MIF) [130]; SOX9 and EGFR, associated with astrocyte development and differ-
entiation; CHCHD2, showing coamplification with the well-known GBM marker, EGFR,
in glioma [131,132]; the transcriptomic factor SOX9, involved in brain development and
lineage specification, with an established oncogenic role in gliomas [126,133]; PSAP, a target
for glioma treatment, by promoting glioma cell proliferation via the TLR4/NF-kB signaling
pathway [134]; PREX1 and ABHD2, shown to promote tumor invasion and progression
in GBM [135]; and the tumor suppressor BIN1, regulated by HNRNPA2B1 and a putative
proto-oncogene in GBM [136]. The relevance of the genes identified was confirmed by their
significance in the survival outcomes from a bulk GBM RNA-seq dataset (TCGA), as well
by their association with several Gene Ontology (GO) biological process terms.
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2.5. Causal Discovery
The discovery of the causal relationships in complex molecular networks is a challeng-
ing problem that has recently attracted many researchers in the field of cancer genomics,
to overcome the fact that measures of association do not reveal the direction of the esti-
mated association. The identification of causal relationships within molecular paths is
crucial to unveil cancer disease dynamics and therapeutic targets.
Zhang and co-authors (2018) [45] extended module detection and trans-omics network
discovery (see Sections 2.2 and 2.3) to disclose the causal role of long non-coding RNAs
(lncRNAs) on messenger RNAs (mRNAs). lncRNAs interact with mRNAs through gene
regulatory networks to carry out biological functions, such as cell differentiation, cell
proliferation, and cytoprotective programs [137]. The authors proposed module-specific
lncRNA-mRNA causal regulatory networks (MSLCRN) (Table 1), a method aimed at
inferring and analyzing module-specific lncRNA-mRNA causal regulatory networks.
MSLCRN is a three-step procedure to infer module-specific lncRNA-mRNA causal
regulatory networks. The method first identifies lncRNA-mRNA coexpression modules
using WGCNA [37]. Second, the causal effect of lncRNA on mRNA in the causal pairs in
each module identified is estimated using the intervention calculus when the DAG is absent
(IDA) algorithm [138], in two steps: (i) using the parallel-PCalgorithm [44,139] (Table 1),
a parallel version of the PC algorithm [140], to learn the causal structures, or directed acyclic
graphs (DAGs), where the nodes are the lncRNAs or mRNAs and the edges between two
nodes represent the causal relationship between them; and (ii) estimating the causal effects
of lncRNAs on mRNAs by applying do-calculus [141]. A global lncRNA–mRNA causal reg-
ulatory network was finally identified, by integrating the module-specific lncRNA–mRNA
causal regulatory networks.
In an application of MSLCRN to matched expression data of 9704 lncRNAs and
18,282 mRNAs in 451 GBM samples [142], twenty-three lncRNA-mRNA causal regulatory
networks were identified. In subsequent Gene Ontology (GO) and KEGG enrichment
analyses to assess the biological meaningfulness of the MSLCRN networks identified,
fifteen out of the 23 (65.2%) networks were found significantly enriched in at least one GO
biological process or KEGG pathway.
Plaisier et al. (2016) [143] developed the TF-target gene interaction database and the
Systems Genetics Network Analysis (SYGNAL) pipeline (Table 1), for dissecting GBM-
related causal transcriptional regulatory networks (TRNs) and predicting drug targets,
based on multi-omics and clinical patient data. The SYGNAL pipeline uses correlative,
causal, and mechanistic inference approaches to infer the causal flow from mutations to
regulators (TFs and miRNAs) and their downstream target genes.
The authors hypothesized that a TRN describing TF-miRNA regulatory interactions
would be helpful for prioritizing combinatorial interventions and drive therapeutic research
to the development of therapies targeting TFs and miRNAs. Such a TRN is potentially more
effective than single TF and miRNA targeted therapies, by the regulation of several genes
involved in diverse oncogenic processes. The SYGNAL pipeline was applied to the multi-
omics TCGA GBM data. The resulting gbmSYGNAL network predicted 67 novel regulators
(TFs and miRNAs) associated with patient survival or oncogenic processes. Among the
relevant findings of the gbmSYGNAL network, the network revealed modulation of IRF1
by mutated NF1 and PIK3CA to increase tumor lymphocyte infiltration.
More recently, Liu and co-workers (2020) [47] developed a computational pipeline,
Integrative Modeling of Transcription Regulatory Interactions for Systematic Inference of
Susceptibility in Cancer (inTRINSiC) (Table 1), to dissect the TF regulatory circuitry under-
lying the heterogeneity of GBM based on the integration of epigenomic, transcriptomic,
protein interaction, and genetic perturbation. The inTRINSiC pipeline runs in two main
steps. The first step encompasses procedures for constructing context-specific regulatory
networks that readily accommodate additional mechanisms of transcription regulation.
In the second step, context-specific networks are used to perform in silico perturbation
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analysis and infer the dependency on TFs by each subtype, through simulation of the
information flow from the TF regulation layer to the protein signaling layer.
The platform was applied to sample data from the Cancer Cell Line Encyclopedia
(CCLE) [35], TCGA, and the Chinese Glioma Genome Atlas (CGGA) project (Table 1),
enabling the identification of the differential regulatory activity of TFs across different
GBM subtypes. In the subsequent in silico perturbation analysis, the authors identified
MYBL2, a member of the MYB family of transcription factors associated with cell cycle
progression and maintenance of cells in an undifferentiated state [144], as a transcription
factor essential for the proneural subtype, affecting patient survival, in which patients with
low MYBL2 expression showed significantly longer survival [47].
Bayesian networks (BNs) are a type of directed acyclic graph (DAG), where each node
is a random variable and each edge represents a conditional probabilities relationship
between a given pair of nodes. BNs can be used to infer regulatory networks, through
the identification of the conditional probabilities, which in turn can be used to infer the
direction of information flow within the network and hypothesize putative underlying
causal relationships between the nodes. Kaiser et al. (2017) [145] used Bayesian inference
to disclose changes in the extracellular regulatory network related to host immunity and
co-occurring with oncogenesis, such as an increase in cell proliferation and epithelial-
to-mesenchymal transition (EMT). The authors used TCGA gene expression data from
tumor and normal breast cancer tissue samples, combined with defined gene signatures,
the metagenes, which represented groups of genes, instead of single genes, associated
with the processes of interest, either immune or cancer related. Although the study was
developed for breast cancer data, the authors investigated other cancer types, namely GBM,
to determine whether the relationships inferred were breast cancer-specific or not.
The Bayesian networks were generated from the metagene constructs using an incre-
mental associated Markov blanket (IAMB) algorithm [146] implemented in the bnlearnR
package (Table 1). The IAMB algorithm starts with a forward phase that generates a net-
work by maximizing the conditional independence of the nodes, followed by a backward
phase that removes one-by-one any remaining conditionally independent connections.
The use of metagene constructs was intended to simplify the DAG, by reducing the dimen-
sion to a low number of less computationally expensive and interpretable nodes, and help
eliminating noise in the data. Confidence for the edges was calculated using a bootstrap
resampling strategy, by randomly sampling patient data with replacement, with a network
generated from the new dataset in each replicate.
In the resulting breast and GBM networks, increased proliferation led to increases
in M1 polarized macrophages associated with increases in natural killer cell infiltration
in GBM. When using only cancer samples, however, the relationship between EMT and
macrophage polarization in the network reemerged. The authors reasoned that these
differences might be related to the fact that GBM arises in an immune-privileged area.
Kunkle et al. (2013) [147] developed a meta-analysis of 12 microarray studies on
normal and astrocytoma tissues, followed by a Bayesian analysis of the results of this
meta-analysis. The goal was to identify key genes and/or pathways in the development
of astrocytic tumors. The analysis pipeline involved the identification of a significant set
of de-regulated genes across the microarray studies considered, enrichment and network
analyses of the significant genes and investigation and validation of the network analysis.
The Bayesian networks were inferred using the Banjo (Duke University, NC) soft-
ware (Table 1), which performs Bayesian structure inference based on Dirichlet scoring.
The Bayesian network genes in each stage of astrocytoma (grades I–IV) were used to
identify key genes in the development of astrocytoma, through the identification of a set
of Markov blanket genes from each gene network, which stands, for a given node, as the
set of the parents, children, and the children’s parents. In the resulting GBM (grade IV)
network inferred, the most influential genes, COL4A1, EGFR, BTF3, MPP2, RAB31, CDK4,
CD99, ANXA2, TOP2A, and SERBP1, were able to accurately predict non-tumor and tumor
cases [147]. Some of those genes have been reported to be highly expressed or activated
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in GBM, e.g., EGFR [17], BTF3 [148], CD99 [149,150], TOP2A [151], and SERBP1 [152].
Moreover, the analysis of gene-gene interactions revealed joint effects of changes in the ex-
pression of Markov blanket genes in the risk for developing GBM, which was dramatically
increased with joint effects of four to 10 Markov blanket genes, resulting in a 9 to 85.9%
increase, respectively, compared to the normal population [147].
In the BN research vein as well, Cai et al. (2019) [153] proposed a tumor-specific com-
putational framework based on Bayesian causal modeling, tumor-specific causal inference
(TCI), to estimate the causal relationships between somatic genome alterations (SGAs)
and molecular phenotypes (e.g., transcriptomic, proteomic) observed in an individual
tumor. TCI integrates multiple types of SGAs and molecular phenotypes to estimate which
genome perturbations are causally influencing one or more molecular/cellular pheno-
types in an individual tumor. TCI was applied to 5097 tumors across 16 cancer types in
TCGA, including GBM, to derive tumor-specific causal network models. TCI identified
634 causative SGAs of cancer-related DEGs in a significant number of tumors. TCI inferred
statistically robust causal relationships, which were further supported by computational
and experimental analyses.
In another branch of causal discovery, Mendelian randomization (MR) uses genetic
variants, such as single-nucleotide polymorphisms (SNPs), that are robustly associated
with an exposure as proxies for the risk factor of interest [154], therefore eliminating con-
founding and reverse causation effects between the exposure of interest and outcome.
Howell et al. (2020) [155] used MR to assess the causal relationship of associations of
36 reported glioma risk factors obtained from a systematic MEDLINE search on observa-
tional epidemiology studies. A meta-analysis of two glioma genome-wide association
studies (GWASs) was then performed, and a two-sample MR analysis using the GWAS
exposure and outcome datasets investigated the causal relationships between the risk
factors identified and glioma incidence. The MR analysis revealed that four genetically
predicted traits increased the risk of glioma, GBM, or non-GBM, namely longer leukocyte
telomere length, liability to allergic disease, increased alcohol consumption, and liability to
childhood extreme obesity. On the other hand, two traits, increased low-density lipoprotein
cholesterol (LDLc) and triglyceride levels, decreased the risk of non-GBM cancers.
3. Major Challenges and Future Strategies
The enormous quantity of multi-omics data generated in recent cancer-related studies
and the software tools able to perform network analyses portrayed in this review must be
further explored, integrated, and made available to wider audiences. It is still crucial to
better identify which genes involved in a particular network are truly clinically relevant.
As denoted by the authors that developed the WGCNA software, the large list of hub genes
identified in the analysis might be further shortened based on some filtering strategies,
such as the availability of protein biomarkers and mouse models for validation, biological
relevance based on ontology data, and the capacity to be used as a therapeutic target [50].
The information gathered from network analyses is expected to help in the prediction of
tumor characteristics and, ultimately, assist in precision medicine approaches that might
influence clinical decisions.
Having in mind the tremendous effect that these data can have in the clinical setting,
the need for validation of the utility of particular networks is undeniable. Studies from
Horvath et al. (2006) [50] perfectly described the workflow of the identification of a network
to the clinical validation, from bioinformatics analyses to in vitro studies and the search
for clinical significance. This study led to the identification of the ASPM gene [50], and
its relevance was further validated both by the same authors and in other groups [50,55],
as detailed in Section 2.2. Similarly, the functional relevance of SERBP1, identified in a
Bayesian network [147], was further evaluated by an independent study [152].
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The validation of molecular networks might be performed by testing key genes in
genetically-manipulated GBM models, combined with pharmacological approaches for
the activation/inhibition of the target, using both cell lines and patient-derived cultures,
to evaluate functional effects and omics alterations. Complementing in vitro findings
with in vivo models of GBM, including syngeneic and xenograft mice models, is also of
critical translational relevance. In the last few decades, some novel in vitro and in vivo
models have emerged, which attempt to surpass some of the limitations and simplicities of
homotypic in vitro cultures with GBM cell lines. For example, organoids with heterotypic
cultures can be grown from a patient tumor tissue and be used for therapy response
evaluations [156]. Different studies showed that GBM organoids better recapitulate the
parental tumor, maintaining the critical cellular and molecular heterogeneity and muta-
tional profiles of particular tumor niches [157,158]. Beyond these advantages, organoids
also allow the establishment of heterotypic cultures, in which non-tumor cells (i.e., im-
mune cells, endothelial cells, etc.) that are commonly present in the original tumor can
be co-cultured with exogenous cells, better mimicking the tumor microenvironment [159].
At the in vivo level, patient-derived xenografts (PDXs), in which a patient tumor is directly
implanted in immunodeficient mice, have also emerged as a promising approach to bet-
ter reflect the various aspects of tumor pathophysiology, heterogeneity, and response to
therapy [160–162]. Orthotopic PDXs of GBM have been shown to preserve tumor mor-
phology, invasion patterns, and critical molecular aberrations, such as alterations of TERT,
EGFR, PTEN, TP53, BRAF, and IDH1. On the contrary, necrosis and microvascular pro-
liferation seem to be lost upon engraftment, as is the case for some molecular alterations,
including PDGFRA amplification [163]. PDXs represent excellent models to study and/or
validate molecular networks, as they better maintain GBM heterogeneity and predict
therapy responses. In fact, recent studies have been trying to find correlations between
genotypic profiles/signatures and the response to standardized treatments of GBM using
PDXs [164,165]. Another recent innovation is related to liquid biopsies in the context of
cancer, in which cancer-relevant biomarkers are assessed in body fluids (e.g., blood, urine,
cerebrospinal fluids, and ascites) [166,167]. Contrary to tumor tissue biopsy, liquid biopsies
are noninvasive, allowing more frequent sample collection and monitoring of the tumor
evolution longitudinally [2,168]. In particular for gliomas, the majority of studies have
used blood samples and cerebrospinal fluid, and a residual number of reports evaluated
urine samples [169]. Miller et al. (2019) [170] identified a genomic landscape of glioma
based on cerebrospinal fluid that resembled the primary tumor, highlighting how liquid
biopsies could be used to track glioma. Considering the intra- and inter-tumor hetero-
geneity of GBM, and its evolution, future studies should critically focus on how network
analyses might assist the evaluation of omics data generated from liquid biopsies, which
may facilitate and improve the level of examination of tumor dynamics, better predicting
tumor progression and therapy responses. Molecular network models will also be pivotal
in (near) single-cell analyses [171], depicting the multiple genetic patterns of individual
cells that constitute a single tumor, potentially aiding in the selection and development
of anti-GBM targeted therapies that may improve clinical responses, in a paradigm of
precision medicine.
4. Conclusions
This narrative review summarizes the network-based strategies for network discovery
and disease outcome prediction and the main findings when applied to GBM studies,
along with the software developed and open challenges and future research opportunities.
The role of network discovery has long been investigated in biological data, continuously
challenged by the fast-growing technological advances. In the particular case of cancer
genomics, advanced network-based algorithmic and computational tools are required to
translate the vast amounts of high-dimensional and heterogeneous data into molecularly-
informed clinical decisions. Trends in network discovery show a paradigm shift from
association to causal discovery, with the premise that causal relationships disclose the
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direction of the association, therefore more meaningful for targeted interventions. While
the development of causal inference methods rapidly evolves across several scientific
domains, its application to GBM has been seldom investigated. Future GBM network-based
studies might encompass a deeper focus of the causal nature of the biological mechanisms
behind GBM, further contributing to our scientific understanding of this deadly disease
and potentially improving clinical practice.
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CSPRV Cancer subtype prediction using R2
DAG Directed acyclic graph
DEG Differential expressed gene
DiME Disease module extraction
DINGO Differential network analysis in genomics
EMT Epithelial-to-mesenchymal transition
EPoC Endogenous perturbation analysis of cancer
GBM Glioblastoma multiforme
GBM-BioDP Glioblastoma Bio Discovery Portal
GEO Gene Expression Omnibus
GMM Gaussian mixture model
GO Gene Ontology
GWAS Genome-wide association study
HGG High-grade glioma
IAMB Incremental associated Markov blanket
IDA Intervention calculus when the DAG is absent
iDINGO Integrative differential network analysis in genomics
InTRINSiC
Integrative Modeling of Transcription Regulatory Interactions for
Systematic Inference of Susceptibility in Cancer
KEGG Kyoto Encyclopedia of Genes and Genomes
KINC Knowledge Independent Network Construction
LGG Low-grade glioma
TCGA The Cancer Genome Atlas
CCLE Cancer Cell Line Encyclopedia
CGGA Chinese Glioma Genome Atlas
EN Elastic net
lasso Least absolute shrinkage selection operator
lncRNA Long non-coding RNA
MI Mutual information
MSLCRN Module-specific lncRNA-mRNA causal regulatory networks
NGS Next-generation sequencing
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PDX Patient-derived xenograft
RNA-seq RNA sequencing
scRNA-seq Single-cell RNA sequencing
SNF Similarity Network Fusion
SNP Single-nucleotide polymorphism
SYGNAL Systems Genetics Network Analysis
TAM Tumor-associated macrophage
TCI Tumor-specific causal inference
TF Transcriptional factor
TRN Transcriptional regulatory network
twiner Twin networks recovery
WGCNA Weighted gene coexpression network analysis
WSNF Weighted similarity network fusion
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